熱門資訊> 正文
罕见疾病疗法接受FDA审查，伊顿公学股价上涨
2024-07-16 19:26
- Shares of Eton Pharmaceuticals (NASDAQ:ETON) traded higher in the premarket Tuesday after the company said the U.S. Food and Drug Administration (FDA) accepted its marketing application for its rare disease therapy ET-400.
- A liquid formulation of hydrocortisone designed for oral administration, ET-400 targets children with hormonal conditions such as adrenocortical insufficiency, a relatively rare disease marked by an inability to produce cortisol.
- Eton (ETON) said that the FDA accepted its new drug application for ET-400, issuing February 28, 2025, as the agency's target action date.
- “The acceptance of our NDA is a significant milestone toward our efforts of bringing this important and highly in-demand liquid formulation to children,” CEO Sean Brynjelsen said, adding that the company expects to launch the product next year.
More on Eton Pharmaceuticals
- Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Eton Pharmaceuticals
- Historical earnings data for Eton Pharmaceuticals
- Financial information for Eton Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
